CoChat

Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming

The DOI matches its Crossref record.

Abstract

Adoptive immunotherapy for cancer has been limited by a lack of antigen specificity, low levels of target expression, and failure to break self-tolerance. We hypothesized that infusion of genetically modified tumor-specific T cells following autologous stem cell transplant (ASCT) may overcome these barriers for multiple myeloma (MM). To test this, we conducted a phase I/II clinical trial (NCT01352286) in which T cells engineered with an HLA-A*0201 restricted, affinity-enhanced TCR recognizing NY-ESO-1 / LAGE-1 peptides (NY-ESOc259-T), were infused in the setting of profound lymphodepletion that accompanies high-dose chemotherapy given with ASCT. HLA-A*0201 MM patients eligible for ASCT, with antigen positive tumor were enrolled. NY-ESOc259-T was manufactured in a 10 day process using anti-CD3/CD28 microbeads and lentiviral vector, and was administered two days following ASCT. IMWG criteria were used to assess response at day 100 with the addition of a near complete response category (nCR) due to the common occurrence of oligoclonal banding observed following rapid post-ASCT immune reconstitution. Blood and marrow samples were taken at multiple timepoints for serum cytokine analysis, NY-ESOc259-T persistence and trafficking, multiparameter flow analysis to examine the phenotype and function of NY-ESOc259-T, and tumor biomarker analysis. 25 of 29 enrolled patients were infused. A mean of 2.8 × 109 engineered cells were administered (range 8.3 × 108-4.2 × 109), and the average transduction efficiency was 33% (range 30%-45%). Patients tended to have advanced disease (64% chromosomal abnormalities, and 24% prior ASCT). At 3 months, 67% (16/24) and 58% (14/24) of patients were in VGPR and nCR or better, respectively. Infusions were well-tolerated and no cytokine release syndrome was reported. NY-ESOc259-T persisted at 6 months in all but one patient, and in a subset of patients at 2 years; marrow infiltration was consistently observed from day 7 through day 180. NY-ESOc259-T initially displayed a dominant activated effector phenotype which converted towards a dominant effector memory phenotype by 1 year post infusion, in a pattern that mirrored clinical responses. Persisting cells demonstrated a polyfunctional response (IFN-γ and TNF-α) with a cytotoxic (CD107a and granzyme B) signature without overexpression of exhaustion markers (PD-1, LAG-3, and TIM-3). Tumor biomarker analysis is ongoing. MM relapse occurred in 13/25 patients. This data show that NY-ESOc259-T cells exhibit robust trafficking and expansion, durable persistence without exhaustion, and follow a natural immune expansion and contraction pattern consistent with an antigen-driven mechanism of action. Relapse correlated with a loss of persistence or tumor antigen escape, suggesting that targeting multiple antigens and maintenance infusions may increase durable remissions. Citation Format: Aaron Rapoport, Edward Stadtmauer, Luca Melchiori, Ryan Wong, Eduardo Davila, Gwendolyn Binder-Scholl, Tom Holdich, Dan Vogl, Brendan Weiss, Jeffrey Finkelstein, Simon Lacey, Sarah Bond, Marylene Fortin, Yoav Peretz, Joanna Brewer, Alan Bennett, Andrew Gerry, Nick Pumphrey, Helen Tayton-Martin, Lilliam Ribeiro, Ashraf Badros, Saul Yanovich, Nancy Hardy, Jean Yared, Naseem Kerr, Sunita Philip, Sandra Wesphal, Bruce L. Levine, Carl June, Michael Kalos, Bent Jakobsen. NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4701. doi:10.1158/1538-7445.AM2015-4701

Overview

Integrity signals

Registry

Crossref · 10.1158/1538-7445.am2015-4701

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

  • Clinical use of lentiviral vectors

    Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930

    “In a trial using a lentiviral vector to transfer a TCR specific for a peptide that was shared by NY-ESO-1 and LAGE-1 as a therapy for patients with multiple myeloma, clinical responses were observed in 16 of 20 patients, with minimal safety concerns [72].”
    Background

See all 1

Metadata

Authors
Rapoport, A., Stadtmauer, E., Melchiori, L., Wong, R., Davila, E., Binder-Scholl, G., Holdich, T., Vogl, D., Weiss, B., Finkelstein, J., Lacey, S., Bond, S., Fortin, M., Peretz, Y., Brewer, J., Bennett, A., Gerry, A., Pumphrey, N., Tayton-Martin, H., Ribeiro, L., Badros, A., Yanovich, S., Hardy, N., Yared, J., Kerr, N., Philip, S., Wesphal, S., Levine, B. L., June, C., Kalos, M., & Jakobsen, B.
Affiliations
  • University of Maryland, Baltimore (US)
  • University of Pennsylvania (US)
  • Adaptimmune (United Kingdom) (GB)
  • 1University of Maryland at Baltimore, Baltimore, MD;
  • 4Adaptimmune, PA;
  • 5Cambridge Biomedical, MA;
  • 6Immunecarta, Montreal, Quebec, Canada.
Venue
Cancer Research
Published
2015-08-01
Volume
75
Issue
15_Supplement
Pages
4701-4701
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2327586678
Cited by
1
References
0
Citations by year
2018: 1
Type
conference abstract
Language
en
Open access
closed
Locations
Cancer Research (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Keywords
NY-ESO-1, multiple myeloma, adoptive T cell therapy, autologous stem cell transplantation, T cell exhaustion, T cell memory, effector T cells, lentiviral vectors, HLA-A*0201, T cell persistence, cytokine release syndrome, high-dose chemotherapy, oligoclonal bands

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming. https://app.cochat.ai/papers/10.1158/1538-7445.am2015-4701
The paper
Rapoport, A., Stadtmauer, E., Melchiori, L., Wong, R., Davila, E., Binder-Scholl, G., Holdich, T., Vogl, D., Weiss, B., Finkelstein, J., Lacey, S., Bond, S., Fortin, M., Peretz, Y., Brewer, J., Bennett, A., Gerry, A., Pumphrey, N., Tayton-Martin, H., . . . Jakobsen, B. (2015). Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming. Cancer Research. https://doi.org/10.1158/1538-7445.am2015-4701

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.